Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies

The prognosis of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is poor. Chimeric antigen receptor (CAR) T-cell therapy has been approved for R/R DLBCL after 2 prior lines of therapy based on data from single-arm phase 2 trials, with complete responses (CRs) in 40%...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood Adv
Asıl Yazarlar: Sermer, David, Batlevi, Connie, Palomba, M. Lia, Shah, Gunjan, Lin, Richard J., Perales, Miguel-Angel, Scordo, Michael, Dahi, Parastoo, Pennisi, Martina, Afuye, Aishat, Silverberg, Mari Lynne, Ho, Caleb, Flynn, Jessica, Devlin, Sean, Caron, Philip, Hamilton, Audrey, Hamlin, Paul, Horwitz, Steven, Joffe, Erel, Kumar, Anita, Matasar, Matthew, Noy, Ariela, Owens, Colette, Moskowitz, Alison, Straus, David, von Keudell, Gottfried, Rodriguez-Rivera, Ildefonso, Falchi, Lorenzo, Zelenetz, Andrew, Yahalom, Joachim, Younes, Anas, Sauter, Craig
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2020
Konular:
Clinical Trials and Observations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7556134/
https://ncbi.nlm.nih.gov/pubmed/33002134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002118
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller